

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT:	Phillips)	ATTORNEY DOCKET:	04242350
)		
SERIAL NO.:	10/797374)	GROUP ART UNIT:	1615
)		
FILED:	March 10, 2004)	EXAMINER:	Unknown
)		
TITLE:	Novel Substituted Benzimidazole Dosage Forms and Method of Using Same			
DATE:	May 30, 2006		CUSTOMER NO.:	26565

Commissioner for Patents
PO BOX 1450
Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.97(b)

Applicant hereby submits copies of patents, publications and/or other information of which they are aware and which may be related to the examination of this application, and in respect of which there may be a duty to disclose under 37 CFR § 1.56 and §§ 1.97 - 1.987 as supplemented by MPEP § 609. A list of all enclosed documents is provided in a Form PTO-1449, transmitted herewith. Presentation of documents listed on enclosed Form PTO-1449 is not an admission that any listed document is prior art under the Patent Statutes and the right is reserved to antedate any material described in the listed documents by a showing under 37 C.F.R. § 1.131 or otherwise.

This information disclosure statement is being filed within three months of the filing date of the above-cited patent application or prior to the mailing of a first Office action on the merits, in accordance with 37 CFR § 1.97(b). Accordingly, Applicant respectfully requests that the statement be considered by the Office in the course of prosecution of the application. No fee is believed payable; however, if it is determined that a fee is payable, please charge Deposit Account No. 13-0019.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 CFR §1.97(g)), an admission that the information cited is or is considered to be material to patentability, or that no other material information exists.

Respectfully submitted,

David B. Fournier
Registration No. 51,696
Tel. 312-701-8034

This document is identified by U.S. Patent & Trademark Office (USPTO) as follows: This information is required to obtain certain benefits from the public which will result from the USPTO's processing of your application. Confidentiality is provided by 35 U.S.C. 102 and 37 CFR 1.61. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time spent depending upon the individual case. Any questions on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20591. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send TO Commissioner for Patents, P.O. Box